PMID- 22145703
OWN - NLM
STAT- MEDLINE
DCOM- 20120829
LR  - 20181201
IS  - 1937-335X (Electronic)
IS  - 1937-3341 (Linking)
VI  - 18
IP  - 9-10
DP  - 2012 May
TI  - A comparison of human smooth muscle and mesenchymal stem cells as potential cell 
      sources for tissue-engineered vascular patches.
PG  - 986-98
LID - 10.1089/ten.TEA.2011.0172 [doi]
AB  - In pediatric patients requiring vascular reconstruction, the development of a 
      cell-based tissue-engineered vascular patch (TEVP) has great potential to 
      overcome current issues with nonliving graft materials. Determining the optimal 
      cell source is especially critical to TEVP success. In this study, we compared 
      the ability of human aortic smooth muscle cells (HuAoSMCs) and human mesenchymal 
      stem cells (hMSCs) to form cell sheets on thermoresponsive 
      poly(N-isopropylacrylamide) (PIPAAm) substrates. hMSCs treated with transforming 
      growth factor beta 1 (TGFbeta1) and ascorbic acid (AA) had higher expression of 
      SMC-specific proteins compared to HuAoSMCs. hMSCs also had larger cell area and 
      grew to confluence more quickly on PIPAAm than did HuAoSMCs. hMSCs typically 
      formed cell sheets in 2-3 weeks and had greater wet tissue weight and collagen 
      content compared with HuAoSMC sheets, which generally required growth for up to 5 
      weeks. Assays for calcification and alkaline phosphatase activity revealed that 
      the osteogenic potential of TGFbeta1+AA-treated hMSCs was low; however, Alcian Blue 
      staining suggested high chondrogenic behavior of TGFbeta1+AA-treated hMSCs. Although 
      hMSCs are promising for cell-based TEVPs in their ability to form robust tissue 
      with significant extracellular matrix content, improved control over hMSC 
      behavior will be required for long-term TEVP success.
FAU - Williams, Corin
AU  - Williams C
AD  - Department of Biomedical Engineering, Boston University, Boston, Massachusetts 
      02215, USA.
FAU - Xie, Angela W
AU  - Xie AW
FAU - Emani, Sirisha
AU  - Emani S
FAU - Yamato, Masayuki
AU  - Yamato M
FAU - Okano, Teruo
AU  - Okano T
FAU - Emani, Sitaram M
AU  - Emani SM
FAU - Wong, Joyce Y
AU  - Wong JY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120126
PL  - United States
TA  - Tissue Eng Part A
JT  - Tissue engineering. Part A
JID - 101466659
RN  - 0 (Acrylamides)
RN  - 0 (Acrylic Resins)
RN  - 0 (Polymers)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 25189-55-3 (poly-N-isopropylacrylamide)
RN  - PQ6CK8PD0R (Ascorbic Acid)
SB  - IM
MH  - Acrylamides/chemistry
MH  - Acrylic Resins
MH  - Ascorbic Acid/pharmacology
MH  - Blotting, Western
MH  - Chondrogenesis/drug effects/physiology
MH  - Humans
MH  - Mesenchymal Stem Cells/*cytology/drug effects
MH  - Myocytes, Smooth Muscle/*cytology/drug effects
MH  - Osteogenesis/drug effects/physiology
MH  - Polymers/chemistry
MH  - Tissue Engineering/*methods
MH  - Tissue Scaffolds/chemistry
MH  - Transforming Growth Factor beta1/pharmacology
EDAT- 2011/12/08 06:00
MHDA- 2012/08/30 06:00
CRDT- 2011/12/08 06:00
PHST- 2011/12/08 06:00 [entrez]
PHST- 2011/12/08 06:00 [pubmed]
PHST- 2012/08/30 06:00 [medline]
AID - 10.1089/ten.TEA.2011.0172 [doi]
PST - ppublish
SO  - Tissue Eng Part A. 2012 May;18(9-10):986-98. doi: 10.1089/ten.TEA.2011.0172. Epub 
      2012 Jan 26.